Clinical Trial Update: Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating liposomal doxorubicin, bevacizumab, and everolimus in locally advanced triple-negative breast cancer predicted insensitive to standard …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Invasive Breast Carcinoma
• Triple-negative Breast Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Everolimus (everolimus)
• liposomal doxorubicin (doxorubicin liposomal)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2024-02-13